Texas Subject | DIABETES

Filter View [Reset All]
Syndicate content
StanceStateBillStatusSummary/TitleLast Actionsort icon
TXSB241PassRelating to written notification provided by drug manufacturers regarding the cause of generic or biosimilar insulin prescription drug unavailability.
[Detail][Text][Discuss]
2023-05-27
Effective on . . . . . . . . . . . . . . . September 1, 2024
TXHB2529Intro

Sine Die
Relating to written notification provided by drug manufacturers regarding the cause of generic insulin prescription drug unavailability.
[Detail][Text][Discuss]
2023-05-01
To House Public Health Committee
TXHB2891Engross

Sine Die
Relating to the use of glucagon medication on certain public and private school campuses.
[Detail][Text][Discuss]
2023-04-27
To Senate Education Committee
TXSB2535Intro

Sine Die
Relating to the use of prescription glucagon medication on public and private school campuses.
[Detail][Text][Discuss]
2023-03-23
To Senate Education Committee
TXHB3912Intro

Sine Die
Relating to the applicability of health benefit plan cost-sharing requirements for prescription insulin.
[Detail][Text][Discuss]
2023-03-20
To House Health Care Reform, Select Committee
Syndicate content
feedback